Dopavision GmbH is a digital-health startup based in Berlin. Backed with venture capital and a research grant, our goal is to disrupt vision care with digital solutions. Myopia, or shortsightedness, is first: it is a condition that affects billions of people worldwide, and 200 million children are suffering from progressive myopia globally – many of them in South East Asia. We are developing a digital treatment against myopia progression in children in the form of a smartphone app, which will become available for a virtual or augmented reality device, as well as smart glasses. We have completed proof-of-concept experiments with animals and human subjects and are moving into a clinical study. Our existing prototype is evolving into a stable product, based on requirements from users, doctors, and regulators.